Golimumab 50mg/0.5mL (100mg/mL) Injection

Golimumab 50mg/0.5mL (100mg/mL) is a TNF-blocking antibody used for selected inflammatory joint and bowel conditions. It reduces persistent inflammatory signalling in an appropriate treatment regimen.
The 50mg/0.5mL presentation is injected subcutaneously on the condition-specific schedule. Rotate sites and allow refrigerated medicine to warm naturally before injection without shaking it.
Golimumab binds tumour necrosis factor alpha, preventing activation of pathways that sustain immune-mediated inflammation.
Upper respiratory infections, headache, nausea and injection-site reactions can occur. Serious infection and reactivation of tuberculosis or hepatitis B are important risks.
Tuberculosis and hepatitis B screening are considered before treatment. Fever, persistent cough or other signs of infection should be assessed before further doses.
Can reduce inflammatory symptoms and support longer-term disease control in suitable patients.
TNF helps contain some infections, so blocking it can allow latent tuberculosis to reactivate.
No. Loading and maintenance schedules depend on the condition and may use different amounts.
They are generally avoided while TNF-blocking treatment is being used.
Some joint-disease regimens include methotrexate alongside golimumab; the combination is condition-specific.
TNF-alpha: a protein promoting inflammation. Psoriatic arthritis: inflammatory arthritis associated with psoriasis. Latent tuberculosis: inactive TB infection that can reactivate.; AR: Golimumab 50mg/0.5mL (100mg/mL) حقن; FR: Golimumab 50mg/0.5mL (100mg/mL) injection; PT: Golimumab 50mg/0.5mL (100mg/mL) injeção; ES: Golimumab 50mg/0.5mL (100mg/mL) inyección; RU: Golimumab 50mg/0.5mL (100mg/mL) инъекция; ID: Golimumab 50mg/0.5mL (100mg/mL) injeksi; VI: Golimumab 50mg/0.5mL (100mg/mL) thuốc tiêm; MS: Golimumab 50mg/0.5mL (100mg/mL) suntikan; TL: Golimumab 50mg/0.5mL (100mg/mL) iniksyon; ZH-SG: Golimumab 50mg/0.5mL (100mg/mL) 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Golimumab 50mg/0.5mL (100mg/mL) Injection under Immunology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Golimumab 50mg/0.5mL (100mg/mL) Injection